Publications by authors named "A Garcia-Burillo"
Article Synopsis
- There are no established first-line treatments for higher grade gastroenteropancreatic neuroendocrine tumors (NETs), prompting a study on the effectiveness of Lu-DOTA-TATE (Lu-Dotatate) as a potential option.
- The NETTER-2 trial was a phase 3 study that randomized patients with advanced NETs to receive either Lu-Dotatate plus octreotide or high-dose octreotide alone, focusing on progression-free survival as the main outcome.
- Results showed that patients receiving Lu-Dotatate had a significantly longer median progression-free survival of 22.8 months compared to 8.5 months for those on high-dose octreotide, indicating Lu-Dotatate may
Background: Although differentiated thyroid carcinoma (DTC) is the most frequent endocrine pediatric cancer, it is rare in childhood and adolescence. While tumor persistence and recurrence are not uncommon, mortality remains extremely low. Complications of treatment are however reported in up to 48% of the survivors.
View Article and Find Full Text PDFBackground: Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role in certain tumor sites remains unclear. This study sought to elucidate the efficacy and safety of [Lu]Lu-DOTATATE in NENs with different locations and evaluate the effect of the tumor origin, bearing in mind other prognostic variables.
View Article and Find Full Text PDFBackground And Objective: The risk of recurrence in papillary thyroid carcinoma (PTC) is likely related to the amount of tumour in the metastatic lymph node (LN). Therefore, the current TNM classification (N0/N1) make it necessary to find a method to quantify the LN metastasis (LNM). We propose that the quantitative molecular assay One-Step Nucleic-Acid Amplification (OSNA), which measures the number of cytokeratin-19 (CK-19) mRNA copies as a marker of LNM, could play this role.
View Article and Find Full Text PDFBackground: Metastatic small bowel low-grade neuroendocrine tumors (NETs) have a good prognosis. Surgery is the only curative treatment; however, this may induce advanced liver disease, particularly in long-term survivor patients. Acquired hepatocerebral degeneration or Parkinsonism in cirrhosis is characterized by rapidly progressive extrapyramidal symptoms in patients with advanced liver disease.
View Article and Find Full Text PDF